

## **Site visit inspection report on compliance with HTA minimum standards**

### **King's Cell Isolation Unit**

**HTA licensing number 11062**

#### **Licensed for the**

- **processing, storage and distribution of human tissues and cells for human application under the Human Tissue (Quality and Safety for Human Application) Regulations 2007**
- **storage of the body of a deceased person or relevant material which has come from a human body for use for a scheduled purpose**

**25 March 2015**

#### **Summary of inspection findings**

The HTA found the Designated Individual, the Licence Holder, the premises and the practices to be suitable in accordance with the requirements of the legislation.

Although the HTA found that King's Cell Isolation Unit (the establishment) had met the majority of the HTA standards, shortfalls were found, particularly in relation to Governance and Quality systems. These were mainly concerned with written procedures reflecting working practices and the use of pro-forma records.

Particular examples of strengths and good practice are included in the concluding comments section of the report.

#### **The HTA's regulatory requirements**

The HTA must assure itself that the Designated Individual, Licence Holder, premises and practices are suitable.

The statutory duties of the Designated Individual are set down in Section 18 of the Human Tissue Act 2004. They are to secure that:

- the other persons to whom the licence applies are suitable persons to participate in the carrying-on of the licensed activity;
- suitable practices are used in the course of carrying on that activity; and
- the conditions of the licence are complied with.

The HTA developed its licensing standards with input from its stakeholders. They are designed to ensure the safe and ethical use of human tissue and the dignified and respectful treatment of the deceased. The HTA inspects the establishments it licences against four groups of standards:

- consent
- governance and quality systems
- premises facilities and equipment
- disposal.

This is an exception-based report: only those standards that have been assessed as not met are included. Where the HTA determines that a standard is not met, the level of the shortfall is classified as 'Critical', 'Major' or 'Minor' (see Appendix 2: Classification of the level of shortfall). Where HTA standards are fully met, but the HTA has identified an area of practice that could be further improved, advice is given to the DI.

Reports of HTA inspections carried out from 1 November 2010 are published on the HTA's website.

### **Licensable activities carried out by the establishment**

'E' = Establishment is licensed to carry out this activity.

'TPA' = Third party agreement; the establishment is licensed for this activity but another establishment (unlicensed) carries out the activity on their behalf.

<b>Tissue type</b>	<b>Procurement</b>	<b>Processing</b>	<b>Testing</b>	<b>Storage</b>	<b>Distribution</b>
<b>Hepatocytes</b>		<b>E</b>		<b>E</b>	
<b>Pancreatic islets</b>		<b>E</b>		<b>E</b>	<b>E</b>
<b>Vessels</b>				<b>E</b>	<b>E</b>

### **Background to the establishment and description of inspection activities undertaken**

The King's Cell Isolation Unit was set up jointly between the Institute of Liver Studies and the Department of Diabetes and Endocrinology in 2001. The unit isolates hepatocytes and islet cells from donated human liver and pancreas for use in transplantation activities. The unit has service level agreements in place for liver and pancreas procurement. These are in-house with the Liver Transplant Service at King's College Hospital and externally with the NHS blood and transplant service.

In January 2014 processing was moved from a free-standing unit (port-a-cabin) acting as a clean room facility to a new purpose-built facility called the Cellular Therapy Unit (CTU). The CTU has a floor area of 258m<sup>2</sup> and includes space for other processing teams such as

haematopoietic stem cell processing; in addition there are support areas for offices and liquid nitrogen storage. A GMP inspection of the Facility was carried out late 2013.

Hepatocytes and pancreatic islets are isolated in the cell isolation section within CTU. There are separate rooms for hepatocytes and islet isolation activities; each room has a grade C background and contains three laminar flow (LAF) cabinets with work flowing from 'dirty' to 'clean' along the LAFs. The cell isolation unit environment is controlled using an appropriate environmental monitoring system that constantly measures temperature, non-viable air particles and pressure. The system is fully calibrated, tested and maintained annually. Entry to all areas within the CTU is controlled via electronic access and is accompanied by appropriate clothing changes to protect material from contamination. Some areas that are judged to be higher risk, e.g. liquid nitrogen storage, will only allow entry when two individuals with relevant access clearance are present.

Samples for assessment of microbiological contamination are taken during processing procedures and from the final products. Operators are required to validate their aseptic technique annually and three media fill runs were carried out as part of the environmental validation of the new facility.

Hepatocytes are prepared from the fresh liver and either kept fresh in transplant medium at 4°C for up to 24hrs or cryopreserved using a controlled rate freezer. Hepatocytes are not distributed.

Pancreatic islets are prepared from fresh pancreas (max cold ischemic time 12hrs). Islets may be stored fresh for a short period (max 48hrs) whilst practical arrangements for allocation and end use are made; during this period, islets are kept in adherent culture at 37 / 5% CO<sub>2</sub> in standard T175 tissue culture flasks. Final processing of islets takes place immediately prior to release for transplantation. An assessment of the islet equivalent number is made before release. Islet cells may be distributed to other hospitals within the UK.

Donor vessels, removed during organ retrieval, are also stored at the establishment.

A site visit inspection of the King's Cell Isolation Unit was undertaken on 25 March 2015. This was the third routine inspection and included interviews with the DI, heads of processing and Quality Manager. The inspection team conducted a visual inspection of the cell isolation section within the CTU; this was the first visit to the new facility. A document review was carried out and a traceability audit was undertaken. The traceability audit of stored material included three units of cryopreserved hepatocytes; islet material stored for research and stored vessels. Five sets of processing records for hepatocytes and islets were examined. Full traceability was demonstrated, however, some record keeping anomalies were found and these are highlighted in the inspection findings section of the report.

### **Inspection findings**

The HTA found the Designated Individual and the Licence Holder to be suitable in accordance with the requirements of the legislation.

## Compliance with HTA standards

### Governance and Quality

Standard	Inspection findings	Level of shortfall
GQ2 There is a documented system of quality management and audit.		
d) Processes affecting the quality and safety of tissues and / or cells are validated and undergo regular evaluation to ensure they continue to achieve the intended results.	The SOP and authorised PPD describing pancreatic islet preparation states that islets may be stored in culture for up to 24hrs, when in practice pancreatic islets are routinely stored in culture for up to 48hrs. Significant changes to processing should be notified to the HTA and those that have the potential to affect the quality and safety of the cells will require assessment by the HTA. The SOP should also be updated to reflect current working practice.	<b>Minor</b>
GQ4 There is a systematic and planned approach to the management of records.		
a) There are procedures for the creation, identification, maintenance, access, amendment, retention and destruction of records.	<p>The establishment captures processing data on several pro-forma. Several aspects of the processing forms were found to be inadequate. The records for processing contained several examples of overwriting, incomplete fields, transcription errors and data repeatedly captured on the blank reverse side of the record sheet. There seemed to be insufficient space on some of the processing record forms to record the necessary information.</p> <p>Descriptions of processing calculation methodology (e.g. how to calculate target cell concentration for hepatocytes) was not provided in sufficient detail within the appropriate SOP. There were two examples where the incorrect cell concentration was recorded on the hepatocyte processing records.</p>	<b>Minor</b>

GQ6 A coding and records system facilitates traceability of bodies, body parts, tissues and cells, ensuring a robust audit trail.		
c) The establishment has procedures to ensure that tissues and / or cells imported, procured, processed, stored, distributed and exported are traceable from donor to recipient and vice versa.	The procedures for the labelling of cryopreserved hepatocytes were not clearly described in an SOP. Examples were found of cryopreserved hepatocyte bags only labelled with a single identifier, the unique assigned code, using a marker pen directly onto the plastic surface. Labelling of the hepatocytes was inconsistent and not considered sufficiently robust to maintain traceability.	<b>Minor</b>

### Advice

The HTA advises the DI to consider the following to further improve practices:

No.	Standard	Advice
1	GQ1	The DI is advised to document the procedure to describe the decision making process, including consent checks and practical procedures, for when pancreatic islets are rejected for transplantation and instead allocated for research.
2	GQ1	The same container of UW solution can be used for several different batches of islets during processing. The DI is advised to devise a method of tracking the UW usage (i.e. first, second etc.) with each individual batch of islets.
3	GQ1	The procedure for the release of islet cells should clearly define the documents that should accompany the islets on release.
4	GQ4	The service level agreements with end users need to state the responsibility of end users to report end use information back to CTU
5	GQ7	The service level agreement with the NHSBT organ donation and transplantation directorate needs to state that SAEARs should be reported to HTA within 24hrs of discovery by the DI or PD.  The service level agreement with NHSBT needs to be signed. If e-signatures are used this must be made clear.
6	GQ8	A comprehensive Risk Assessment (RA) of the CTU unit design and processes is available dated 2011; however this did not contain an assessment of the islet culture step or the cryopreservation of hepatocytes. The DI is advised to review this RA and include any missing processes.
7	PFE1	The DI is advised to clarify the policy on the use of protective eyewear in the processing facility and ensure this is in line with current working practices.
8	PFE5	There are clear 'return to use forms' for major pieces of equipment post service and repair. These detail whether equipment can be returned to use and the need for any impact assessments where adjustments have been made during service.

		The DI is advised to include the use of these forms to other equipment that may not be judged as 'major' but are critical to processing e.g. peristaltic pumps. It was unclear from service records whether pumps had been calibrated at a speed appropriate to their use or if they had been adjusted during calibration.
--	--	--

**Concluding comments**

There were a number of strengths and areas of good practice observed during this inspection. The new facility provides purpose-built premises for the processing of hepatocytes and islets and monitoring the processing environment. Staff have transitioned efficiently into the new facility with minimal disruption to services. There is an open approach to improvement within the team. The establishment demonstrated a commitment to making full use of donated tissue for research where it is unsuitable for transplantation and appropriate consent is in place.

There are areas of practice that require improvement, including three minor shortfalls. The HTA has given advice to the Designated Individual with respect to procedures, agreements and risk assessments.

The HTA requires that the Designated Individual addresses the shortfalls by submitting a completed corrective and preventative action (CAPA) plan within 14 days of receipt of the final report (refer to Appendix 2 for recommended timeframes within which to complete actions). The HTA will then inform the establishment of the evidence required to demonstrate that the actions agreed in the plan have been completed.

The HTA has assessed the establishment as suitable to be licensed for the activities specified subject to corrective and preventative actions being implemented to meet the shortfall identified during the inspection.

**Report sent to DI for factual accuracy: 23 April 2015**

**Report returned from DI: 05 May 2015**

**Final report issued: 15 May 2015**

**Completion of corrective and preventative actions (CAPA) plan**

Based on information provided, the HTA is satisfied that the establishment has completed the agreed actions in the CAPA plan and in doing so has taken sufficient action to correct all shortfalls addressed in the Inspection Report.

**Date: 3 August 2015**

## Appendix 1: HTA standards

The HTA standards applicable to this establishment are shown below; those not assessed during the inspection are shown in grey text. Individual standards which are not applicable to this establishment have been excluded.

### Human Tissue (Quality and Safety for Human Application) Regulations 2007 Standards

#### Consent

Standard
C1 Consent is obtained in accordance with the requirements of the HT Act 2004, the Human Tissue (Quality and Safety for Human Application) Regulations 2007 and as set out in the HTA's Codes of Practice.
a) If the establishment acts as a procurer of tissues and / or cells, there is an established process for acquiring donor consent which meets the requirements of the HT Act 2004 the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (Q&S Regulations) and the HTA's Codes of Practice
b) If there is a third party procuring tissues and / or cells on behalf of the establishment the third party agreement ensures that consent is obtained in accordance with the requirements of the HT Act 2004, the Q&S Regulations and the HTA's Codes of Practice.
c) The establishment or the third party's procedure on obtaining donor consent includes how potential donors are identified and who is able to take consent.
d) Consent forms comply with the HTA Codes of Practice.
e) Completed consent forms are included in records and are made accessible to those using or releasing tissue and / or cells for a Scheduled Purpose.
C2 Information about the consent process is provided and in a variety of formats.
a) The procedure on obtaining consent details what information will be provided to donors. As a minimum, the information specified by Directions 003/2010 is included.
b) If third parties act as procurers of tissues and / or cells, the third party agreement details what information will be provided to donors. As a minimum, the information specified by Directions 003/2010 is included.
c) Information is available in suitable formats and there is access to independent interpreters when required.
d) There are procedures to ensure that information is provided to the donor or donor's family by trained personnel.
C3 Staff involved in seeking consent receive training and support in the implications and essential requirements of taking consent.
a) Staff involved in obtaining consent are provided with training on how to take informed consent in accordance with the requirements of the HT Act 2004 and Code of Practice on Consent.
b) Training records are kept demonstrating attendance at training on consent.

## Governance and Quality

Standard
GQ1 All aspects of the establishment's work are supported by ratified documented policies and procedures as part of the overall governance process.
a) There is an organisational chart clearly defining the lines of accountability and reporting relationships.
b) There are procedures for all licensable activities that ensure integrity of tissue and / or cells and minimise the risk of contamination.
c) There are regular governance meetings, for example health and safety, risk management and clinical governance committees, which are recorded by agendas and minutes.
d) There is a document control system to ensure that changes to documents are reviewed, approved, dated and documented by an authorised person and only current documents are in use.
e) There are procedures for tissue and / or cell procurement, which ensure the safety of living donors.
f) There are procedures for tissue and / or cell procurement, which ensure the dignity of deceased donors.
g) There are procedures to ensure that an authorised person verifies that tissues and / or cells received by the establishment meet required specifications.
h) There are procedures for the management and quarantine of non-conforming consignments or those with incomplete test results, to ensure no risk of cross contamination.
i) There are procedures to ensure tissues and / or cells are not released from quarantine until verification has been completed and recorded.
j) There are procedures detailing the critical materials and reagents used and where applicable, materials and reagents meet the standards laid down by the European directives on medical devices and in vitro diagnostic medical devices.
k) There is a procedure for handling returned products.
l) There are procedures to ensure that in the event of termination of activities for whatever reason, stored tissues and / or cells are transferred to another licensed establishment or establishments.
m) The criteria for allocating tissues and / or cells to patients and health care institutions are documented and made available to these parties on request.
n) The establishment ensures imports from non EEA states meet the standards of quality and safety set out in Directions 003/2010.
o) There is a complaints system in place.
p) There are written agreements with third parties whenever an activity takes place that has the potential to influence the quality and safety of human tissues and / or cells.
q) There is a record of agreements established with third parties.
r) Third party agreements specify the responsibilities of the third party and meet the requirements set out in Directions 003/2010.

s) Third party agreements specify that the third party will inform the establishment in the event of a serious adverse reaction or event.
t) There are procedures for the re-provision of service in an emergency.
GQ2 There is a documented system of quality management and audit.
a) There is a quality management system which ensures continuous and systematic improvement.
b) There is an internal audit system for all licensable activities.
c) An audit is conducted in an independent manner at least every two years to verify compliance with protocols and HTA standards, and any findings and corrective actions are documented.
d) Processes affecting the quality and safety of tissues and / or cells are validated and undergo regular evaluation to ensure they continue to achieve the intended results.
GQ3 Staff are appropriately qualified and trained in techniques relevant to their work and are continuously updating their skills.
a) There are clearly documented job descriptions for all staff.
b) There are orientation and induction programmes for new staff.
c) There are continuous professional development (CPD) plans for staff and attendance at training is recorded.
d) There is annual documented mandatory training (e.g. health and safety and fire).
e) Personnel are trained in all tasks relevant to their work and their competence is recorded.
f) There is a documented training programme that ensures that staff have adequate knowledge of the scientific and ethical principles relevant to their work, and the regulatory context.
g) There is a documented training programme that ensures that staff understand the organisational structure and the quality systems used within the establishment.
h) There is a system of staff appraisal.
i) Where appropriate, staff are registered with a professional or statutory body.
j) There are training and reference manuals available.
k) The establishment is sufficiently staffed to carry out its activities.
GQ4 There is a systematic and planned approach to the management of records.
a) There are procedures for the creation, identification, maintenance, access, amendment, retention and destruction of records.
b) There is a system for the regular audit of records and their content to check for completeness, legibility and accuracy and to resolve any discrepancies found.
c) Written records are legible and indelible. Records kept in other formats such as computerised records are stored on a validated system.
d) There is a system for back-up / recovery in the event of loss of computerised records.

e) The establishment keeps a register of the types and quantities of tissues and / or cells that are procured, tested, preserved, processed, stored and distributed or otherwise disposed of, and on the origin and destination of tissues and cells intended for human application.
f) There are procedures to ensure that donor documentation, as specified by Directions 003/2010, is collected and maintained.
g) There is a system to ensure records are secure and that donor confidentiality is maintained in accordance with Directions 003/2010.
h) Raw data which are critical to the safety and quality of tissues and cells are kept for 10 years after the use, expiry date or disposal of tissues and / or cells.
i) The minimum data to ensure traceability from donor to recipient as required by Directions 003/2010 are kept for 30 years after the use, expiry or disposal of tissues and / or cells.
j) Records are kept of products and material coming into contact with the tissues and / or cells.
k) There are documented agreements with end users to ensure they record and store the data required by Directions 003/2010.
l) The establishment records the acceptance or rejection of tissue and / or cells that it receives and in the case of rejection why this rejection occurred.
m) In the event of termination of activities of the establishment a contingency plan to ensure records of traceability are maintained for 10 or 30 years as required.
GQ5 There are documented procedures for donor selection and exclusion, including donor criteria.
a) Donors are selected either by the establishment or the third party acting on its behalf in accordance with the criteria required by Directions 003/2010.
b) The testing of donors by the establishment or a third party on behalf of the establishment is carried out in accordance with the requirements of Directions 003/2010.
c) In cases other than autologous donors, donor selection is carried out by authorised personnel and signed and reviewed by a qualified health professional.
d) There is a system in place either at the establishment or at a third party acting on its behalf to record results of donor selection and associated tests.
e) Testing of donor samples is carried out using CE marked diagnostic tests.
f) Samples taken for donor testing are clearly labelled with the time and place the sample was taken and a unique donor identification code.
GQ6 A coding and records system facilitates traceability of tissues and / or cells, ensuring a robust audit trail.
a) There is a donor identification system which assigns a unique code to each donation and to each of the products associated with it.
b) An audit trail is maintained, which includes details of when the tissues and / or cells were acquired and from where, the uses to which the tissues and / or cells were put, when the tissues and / or cells were transferred elsewhere and to whom.
c) The establishment has procedures to ensure that tissues and / or cells imported, procured,

processed, stored, distributed and exported are traceable from donor to recipient and vice versa.
GQ7 There are systems to ensure that all adverse events, reactions and/or incidents are investigated promptly.
a) There are procedures for the identification, reporting, investigation and recording of adverse events and reactions, including documentation of any corrective or preventative actions.
b) There is a system to receive and distribute national and local information (e.g. HTA regulatory alerts) and notify the HTA and other establishments as necessary of serious adverse events or reactions.
c) The responsibilities of personnel investigating adverse events and reactions are clearly defined.
d) There are procedures to identify and decide the fate of tissues and / or cells affected by an adverse event, reaction or deviation from the required quality and safety standards.
e) In the event of a recall, there are personnel authorised within the establishment to assess the need for a recall and if appropriate initiate and coordinate a recall.
f) There is an effective, documented recall procedure which includes a description of responsibilities and actions to be taken in the event of a recall including notification of the HTA and pre-defined times in which actions must be taken.
g) Establishments distributing tissue and / or cells provide information to end users on how to report a serious adverse event or reaction and have agreements with them specifying that they will report these events or reactions.
h) Establishments distributing tissues and / or cells have systems to receive notifications of serious adverse events and reactions from end users and notify the HTA.
GQ8 Risk assessments of the establishment's practices and processes are completed regularly and are recorded and monitored appropriately.
a) There are documented risk assessments for all practices and processes.
b) Risk assessments are reviewed regularly, as a minimum annually or when any changes are made that may affect the quality and safety of tissues and cells.
c) Staff can access risk assessments and are made aware of local hazards at training.
d) A documented risk assessment is carried out to decide the fate of any tissue and / or cells stored prior to the introduction of a new donor selection criteria or a new processing step, which enhances the quality and safety of tissue and / or cells.

### **Premises, Facilities and Equipment**

<b>Standard</b>
PFE1 The premises are fit for purpose.
a) A risk assessment has been carried out of the premises to ensure that they are fit for purpose.
b) There are procedures to review and maintain the safety of staff, visitors and patients.
c) The premises have sufficient space for procedures to be carried out safely and efficiently.

d) Where appropriate, there are procedures to ensure that the premises are of a standard that ensures the dignity of deceased persons.
e) There are procedures to ensure that the premises are secure and confidentiality is maintained.
f) There is access to a nominated, registered medical practitioner and / or a scientific advisor to provide advice and oversee the establishment's medical and scientific activities.
PFE2 Environmental controls are in place to avoid potential contamination.
a) Tissues and / or cells stored in quarantine are stored separately from tissue and / or cells that have been released from quarantine.
b) Where processing of tissues and / or cells involves exposure to the environment, it occurs in an appropriate, monitored environment as required by Directions 003/2010.
c) There are procedures for cleaning and decontamination.
d) Staff are provided with appropriate protective clothing and equipment that minimise the risk of contamination of tissue and / or cells and the risk of infection to themselves.
PFE3 There are appropriate facilities for the storage of tissues and / or cells, consumables and records.
a) Tissues, cells, consumables and records are stored in secure environments and precautions are taken to minimise risk of damage, theft or contamination.
b) There are systems to deal with emergencies on a 24 hour basis.
c) Tissues and / or cells are stored in controlled, monitored and recorded conditions that maintain tissue and / or cell integrity.
d) There is a documented, specified maximum storage period for tissues and / or cells.
PFE4 Systems are in place to protect the quality and integrity of tissues and / or cells during transport and delivery to its destination.
a) There is a system to ensure tissue and / or cells are not distributed until they meet the standards laid down by Directions 003/2010.
b) There are procedures for the transport of tissues and / or cells which reflect identified risks associated with transport.
c) There is a system to ensure that traceability of tissues and / or cells is maintained during transport.
d) Records are kept of transportation and delivery.
e) Tissues and / or cells are packaged and transported in a manner and under conditions that minimise the risk of contamination and ensure their safety and quality.
f) There are third party agreements with courier or transport companies to ensure that any specific transport conditions required are maintained.
g) Critical transport conditions required to maintain the properties of tissue and / or cells are defined and documented.
h) Packaging and containers used for transportation are validated to ensure they are fit for purpose.

i) Primary packaging containing tissues and / or cells is labelled with the information required by Directions.
j) Shipping packaging containing tissues and / or cells is labelled with the information required by Directions.
PFE5 Equipment is appropriate for use, maintained, quality assured, validated and where appropriate monitored.
a) Critical equipment and technical devices are identified, validated, regularly inspected and records are maintained.
b) Critical equipment is maintained and serviced in accordance with the manufacturer's instructions.
c) Equipment affecting critical processes and storage parameters is identified and monitored to detect malfunctions and defects and procedures are in place to take any corrective actions.
d) New and repaired equipment is validated before use and this is documented.
e) There are documented agreements with maintenance companies.
f) Cleaning, disinfection and sanitation of critical equipment is performed regularly and this is recorded.
g) Instruments and devices used for procurement are sterile, validated and regularly maintained.
h) Users have access to instructions for equipment and receive training in the use of equipment and maintenance where appropriate.
i) Staff are aware of how to report an equipment problem.
j) For each critical process, the materials, equipment and personnel are identified and documented.
k) There are contingency plans for equipment failure.

### **Disposal**

<b>Standard</b>
D1 There is a clear and sensitive policy for disposing of tissues and / or cells.
a) The disposal policy complies with HTA's Codes of Practice.
b) The disposal procedure complies with Health and Safety recommendations.
c) There is a documented procedure on disposal which ensures that there is no cross contamination.
D2 The reasons for disposal and the methods used are carefully documented.
a) There is a procedure for tracking the disposal of tissue and / or cells that details the method and reason for disposal.
b) Disposal arrangements reflect (where applicable) the consent given for disposal.

## Human Tissue Act 2004 Standards

<b>Governance and quality system standards</b>
<b>GQ1 All aspects of the establishments work are supported by ratified documented policies and procedures as part of the overall governance process</b>
<ul style="list-style-type: none"><li>• Policies and procedures in place are in place, covering all activities related to the storage of relevant material for research in connection with disorders, or the functioning, of the human body</li><li>• Appropriate risk management systems are in place</li><li>• Regular governance meetings are held; for example, health and safety and risk management committees, agendas and minutes</li><li>• Complaints system</li></ul>
<b>GQ2 There is a documented system of quality management and audit</b>
<ul style="list-style-type: none"><li>• A document control system, covering all documented policies and standard operating procedures (SOPs).</li><li>• Schedule of audits</li><li>• Change control mechanisms for the implementation of new operational procedures</li></ul>
<b>GQ3 Staff are appropriately qualified and trained in techniques relevant to their work and are continuously updating their skills</b>
<ul style="list-style-type: none"><li>• Qualifications of staff and training are recorded, records showing attendance at training</li><li>• Orientation and induction programmes</li><li>• Documented training programme, (e.g. health and safety, fire, risk management, infection control), including developmental training</li><li>• Training and reference manuals</li><li>• Staff appraisal / review records and personal development plans are in place</li></ul>
<b>GQ4 There is a systematic and planned approach to the management of records</b>

<ul style="list-style-type: none"> <li>• Documented procedures for the creation, amendment, retention and destruction of records</li> <li>• Regular audit of record content to check for completeness, legibility and accuracy</li> <li>• Back-up / recovery facility in the event of loss of records</li> <li>• Systems ensure data protection, confidentiality and public disclosure (whistle-blowing)</li> </ul>
GQ5 There are documented procedures for distribution of body parts, tissues or cells
<ul style="list-style-type: none"> <li>• A process is in place to review the release of relevant material to other organisations</li> <li>• An agreement is in place between the establishment and the organisation to whom relevant material is supplied regarding the tracking and use of material and eventual disposal or return</li> </ul>
GQ6 A coding and records system facilitates traceability of bodies, body parts, tissues and cells, ensuring a robust audit trail
<ul style="list-style-type: none"> <li>• There is an identification system which assigns a unique code to each donation and to each of the products associated with it</li> <li>• An audit trail is maintained, which includes details of when and where the relevant material was acquired, the consent obtained, the uses to which the material was put, when the material was transferred and to whom</li> </ul>
GQ7 There are systems to ensure that all adverse events are investigated promptly
<ul style="list-style-type: none"> <li>• Corrective and preventive actions are taken where necessary and improvements in practice are made</li> <li>• System to receive and distribute national and local information (e.g. HTA communications)</li> </ul>
GQ8 Risk assessments of the establishment's practices and processes are completed regularly and are recorded and monitored appropriately
<ul style="list-style-type: none"> <li>• Documented risk assessments for all practices and processes</li> <li>• Risk assessments are reviewed when appropriate</li> <li>• Staff can access risk assessments and are made aware of local hazards at training</li> </ul>

## Premises, facilities and equipment standards

PFE1 The premises are fit for purpose

- A risk assessment has been carried out of the premises to ensure that they are appropriate for the purpose
- Policies in place to review and maintain the safety of staff, authorised visitors and students
- The premises have sufficient space for procedures to be carried out safely and efficiently
- Policies are in place to ensure that the premises are secure and confidentiality is maintained

PFE 2 Environmental controls are in place to avoid potential contamination

- Documented cleaning and decontamination procedures
- Staff are provided with appropriate protective equipment and facilities that minimise risks from contamination
- Appropriate health and safety controls are in place

PFE3 There are appropriate facilities for the storage of bodies, body parts, tissues and cells, consumables and records.

- Relevant material, consumables and records are stored in suitable secure environments and precautions are taken to minimise risk of damage, theft or contamination
- Contingency plans are in place in case of failure in storage area
- Critical storage conditions are monitored and recorded
- System to deal with emergencies on 24 hour basis
- Records indicating where the material is stored in the premises

PFE 4 Systems are in place to protect the quality and integrity of bodies, body parts, tissues and cells during transport and delivery to a destination

- Documented policies and procedures for the appropriate transport of relevant material, including a risk assessment of transportation
- A system is in place to ensure that traceability of relevant material is maintained during transport
- Records of transportation and delivery
- Records are kept of any agreements with recipients of relevant material
- Records are kept of any agreements with courier or transport companies

PFE5 Equipment is appropriate for use, maintained, quality assured, validated and where appropriate monitored

- Records of calibration, validation and maintenance, including any agreements with maintenance companies
- Users have access to instructions for equipment and receive training in use and maintenance where appropriate
- Staff aware of how to report an equipment problem
- Contingency plan for equipment failure

## **Disposal Standards**

D1 There is a clear and sensitive policy for disposing of human organs and tissue

- Documented disposal policy
- Policy is made available to the public
- Compliance with health and safety recommendations

D2 The reason for disposal and the methods used are carefully documented

- Standard operating procedures (SOPs) for tracking the disposal of relevant material detail the method and reason for disposal
- Where applicable, disposal arrangements reflect specified wishes

## Appendix 2: Classification of the level of shortfall (HA)

Where the HTA determines that a licensing standard is not met, the improvements required will be stated and the level of the shortfall will be classified as 'Critical', 'Major' or 'Minor'. Where the HTA is not presented with evidence that an establishment meets the requirements of an expected standard, it works on the premise that a lack of evidence indicates a shortfall.

The action an establishment will be required to make following the identification of a shortfall is based on the HTA's assessment of risk of harm and/or a breach of the HT Act or associated Directions.

### 1. Critical shortfall:

A shortfall which poses a significant direct risk of causing harm to a recipient patient or to a living donor,

*Or*

A number of 'major' shortfalls, none of which is critical on its own, but viewed cumulatively represent a systemic failure and therefore are considered 'critical'.

A critical shortfall may result in one or more of the following:

- (1) A notice of proposal being issued to revoke the licence
- (2) Some or all of the licensable activity at the establishment ceasing with immediate effect until a corrective action plan is developed, agreed by the HTA and implemented.
- (3) A notice of suspension of licensable activities
- (4) Additional conditions being proposed
- (5) Directions being issued requiring specific action to be taken straightaway

### 2. Major shortfall:

A non-critical shortfall.

A shortfall in the carrying out of licensable activities which poses an indirect risk to the safety of a donor or a recipient

*or*

A shortfall in the establishment's quality and safety procedures which poses an indirect risk to the safety of a donor or a recipient;

*or*

A shortfall which indicates a major deviation from the **Human Tissue (Quality and Safety for Human Application) Regulations 2007** or the **HTA Directions**;

*or*

A shortfall which indicates a failure to carry out satisfactory procedures for the release of tissues and cells or a failure on the part of the designated individual to fulfil his or her legal duties;

*or*

A combination of several 'minor' shortfalls, none of which is major on its own, but which,

viewed cumulatively, could constitute a major shortfall by adversely affecting the quality and safety of the tissues and cells.

In response to a major shortfall, an establishment is expected to implement corrective and preventative actions within 1-2 months of the issue of the final inspection report. Major shortfalls pose a higher level of risk and therefore a shorter deadline is given, compared to minor shortfalls, to ensure the level of risk is reduced in an appropriate timeframe.

### **3. Minor shortfall:**

A shortfall which cannot be classified as either critical or major and, which can be addressed by further development by the establishment.

This category of shortfall requires the development of a corrective action plan, the results of which will usually be assessed by the HTA either by desk based review or at the time of the next inspection.

In response to a minor shortfall, an establishment is expected to implement corrective and preventative actions within 3-4 months of the issue of the final inspection report.

## **Follow up actions**

A template corrective and preventative action plan will be sent as a separate Word document with both the draft and final inspection report. You must complete this template and return it to the HTA within 14 days of the issue of the final report.

Based on the level of the shortfall, the HTA will consider the most suitable type of follow-up of the completion of the corrective and preventative action plan. This may include a combination of

- a follow-up site-visit inspection
- a request for information that shows completion of actions
- monitoring of the action plan completion
- follow up at next desk-based or site-visit inspection.

After an assessment of your proposed action plan you will be notified of the follow-up approach the HTA will take.